Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis

被引：2
|
作者：
Kamat, Shweta [1 ]
Patel, Jay [1 ]
Brown, Britny R. [1 ]
Vyas, Ami [1 ]
机构：
[1] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, 7 Greenhouse Rd, Kingston, RI 02881 USA
来源：
CANCER INVESTIGATION | 2022年 / 40卷 / 09期
基金：
美国国家卫生研究院;
关键词：
Nivolumab; ipilimumab; immune checkpoint inhibitors; adverse events; meta-analysis; STAGE IV MELANOMA; PREDICTIVE BIOMARKERS; ADJUVANT NIVOLUMAB; DOUBLE-BLIND; IMMUNOTHERAPY;
D O I：
10.1080/07357907.2022.2108827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
引用
收藏
页码：777 / 788
页数：12
相关论文
共 50 条
  • [41] Nivolumab for newly and recurrent glioblastoma multiforme treatment: A systematic review and meta-analysis
    Moura, Alexandre Wendell Araujo
    Rodrigues, Sirlene da Silva
    de Oliveira, Taciana Freire
    Lobato, Beatriz Marques
    Cerize, Natalia Neto Pereira
    Leo, Patricia
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1736 - 1747
  • [42] Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Xiong, Ding
    Zhang, Kui
    Xu, Mingqing
    PANMINERVA MEDICA, 2023, 65 (04) : 506 - 510
  • [43] Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
    Yang, Wenhan
    Men, Peng
    Xue, Huimin
    Jiang, Mingyan
    Luo, Qiuhua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
    Feng, Yuqian
    Guo, Kaibo
    Jin, Huimin
    Jiang, Jing
    Wang, Menglei
    Lin, Shengyou
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [45] A systematic review with meta-analysis of radiotherapy adverse events in patients with cancer and lupus erythematosus.
    Lopez-Olivo, Maria A.
    Qureshi, Sehrish
    Sharma, Gaurav
    Hicklen, Rachel S.
    Tayar, Jean H.
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis
    Guo, Chang-Ying
    Hang, Si-Cong
    Kuang, Yu-Kong
    Hu, Hao
    JOURNAL OF CANCER, 2019, 10 (01): : 120 - 130
  • [47] Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review
    Tandiono, J.
    Chen, S.
    Marcella, E.
    Susanto, B.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S760
  • [48] Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib plus nivolumab plus /- ipilimumab
    Iannantuono, Giovanni Maria
    Chandran, Elias
    Simon, Nicholas I.
    Ley, Lisa
    Cordes, Lisa M.
    Wang, Tzu-fang
    Girardi, Daniel da Motta
    Gurram, Sandeep
    Valera, Vladimir
    Chalfin, Heather
    Parnes, Howard L.
    Nadal, Rosa
    Niglio, Scot Anthony
    Boudjadi, Salah
    Banday, Abdul Rouf
    Kydd, Andre Rashad
    Steinberg, Seth M.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis
    Yang, Shuheng
    Zhou, Yadong
    Zeng, Lei
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 32 (08): : 839 - 845
  • [50] Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
    Shin, Sangwon
    Moon, Jimin
    Oum, Chiyoon
    Kim, Seulki
    Cho, Soo Ick
    Lim, Yoojoo
    Ock, Chan-Young
    Shin, Seunghwan
    BMC CANCER, 2024, 24 (01)
12345